Article Information
History
- December 11, 2019.
Article Versions
- Version 1 (November 8, 2019 - 02:42).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Simina Ticau, PhD‡,1,
- Gautham V Sridharan, PhD‡,1,
- Shira Tsour, MS1,
- William L Cantley, PhD1,
- Amy Chan, PhD1,
- Jason A Gilbert, MS1,
- David Erbe, PhD1,
- Emre Aldinc, MD1,
- Mary M Reilly, MD2,
- David Adams, MD3,
- Michael Polydefkis, MD4,
- Kevin Fitzgerald, PhD1,
- Akshay Vaishnaw, MD1 and
- Paul Nioi, PhD*,1
- 1Alnylam Pharmaceuticals, 675 West Kendall St, Cambridge, MA, USA
- 2MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK
- 3AP-HP. Université Paris-Saclay, CHU Bicêtre, INSERM U1195, Le Kremlin Bicêtre, France
- 4Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- ↵*Correspondence to: Paul Nioi, Alnylam Pharmaceuticals, 675 W Kendall St, Cambridge, MA 02142, USA., Email: pnioi{at}alnylam.com
↵‡ These authors contributed equally to this work
Posted December 11, 2019.
Plasma proteome analysis of patients with hereditary transthyretin-mediated (hATTR) amyloidosis establishes neurofilament light chain (NfL) as a biomarker of disease and treatment response
